Background: RA is a systemic chronic inflammatory condition that creates a pro-atherogenic state, increasing patients' risk of myocardial infarction (MI). TNF-a plays a major role in stimulating this inflammatory reaction. It is hypothesized that TNF-a antagonists have a secondary role in reducing MI. A literature review was done to investigate if TNF-a antagonists reduce the risk of MI in RA patients. Methods: A literature review was conducted to evaluate if TNF-a antagonists reduce the risk of MI in RA patients. The database of choice was PubMed, and the search terms included rheumatoid arthritis, myocardial infarction, TNF-a and TNF-a antagonist. A cohort study, cross-sectional study, and four case-control studies were reviewed. Results: The BSRBR cohort study showed that overall, patients did not show a reduction in the risk of MI (incidence rate 1.44, 95% Cl 0.56, 367), when compared with patients using traditional DMARDs. However, responders to anti-TNF therapy have a significantly lower incidence rate of MI compared with non-responders (incidence rate 0.36, 95% CI 0.19, 0.69). The QUEST-RA study revealed that prolonged anti-TNF therapy could reduce MI by 58% compared with non-DMARDs (hazard ratio 0.42, 95% CI 0.21, 0.81). A case-control study showed MI risk reduction of 80% for anti-TNF and MTX combination vs MTX monotherapy (RR 0.8, 95% CI 0.05, 0.88). Conclusion: TNF-a antagonists have been proved to show benefits in specific CVD risk factors such as dyslipidaemia, insulin sensitivity and endothelial dysfunction. This review suggests that anti-TNF treatment may benefit in MI incidence reduction. However, more studies focusing at responders to anti-TNF therapy will be required to strengthen this association. Disclosure statement: The authors have declared no conflicts of interest.
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